153 results about "High avidity" patented technology

The application discloses a specific nucleic acid aptamer for a heterogeneous core ribonucleoprotein hnRNPA2B1 and application, and belongs to the technical field of nucleic acid aptamer. The hnRNPA2B1 aptamer is a small single-stranded DNA screened from a designed oligonucleotide library through an in-vitro exponential enrichment ligand system evolution (SELEX), is composed of 80 nucleotides, and has high affinity to the target. The hnRNPA2B1 aptamer can be applied in a detection method or a detection product of the hnRNPA2B1 protein, and a targeted regulation drug or a biological preparation, and can be specifically made into a molecular probe, used as a detection reagent, used as a targeted preparation and the like for diagnosis and treatment of diseases related to the hnRNPA2B1 protein. The hnRNPA2B1 aptamer has strong affinity and specificity, has the advantages of low production cost, stability, convenient synthesis and easy modification compared with an antibody, and is a potential substitute for the antibody in disease diagnosis and treatment.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present application relates to the technical field of antibodies, in particular to a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application provides a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application obtains human SLC19A1 protein by expression and purification through a eukaryotic expression system; then uses the obtained SLC19A1 protein as an immunogen to immunize mice to generate antibodies; finally, a monoclonal antibody specifically recognizing and combining SLC19A1 protein is obtained through flow enrichment and screening, and the epitope recognized and combined by the antibody is identified.It is verified that the monoclonal antibody provided by the present application can specifically recognize and combine the amino acid residues of human SLC19A1 protein, has high affinity, can be used as a molecular tool for detection of SLC19A1 protein, has high sensitivity and specificity, and has application advantages in detection of human SLC19A1 protein.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

To provide a high-affinity monoclonal antibody for a His-tag added to the C terminus of membrane protein.SOLUTION: The present invention provides a monoclonal antibody for a histidine tag (His-tag) or an antigen-binding fragment thereof, wherein the monoclonal antibody recognizes, as an epitope, a His-tag added to the C terminus of a membrane protein.SELECTED DRAWING: None

The invention discloses an RTN4RL2 monoclonal antibody and an application of the RTN4RL2 monoclonal antibody. The monoclonal antibody provided by the invention can specifically target human RTN4RL2, and amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; amino acid sequences of complementary determining regions CDR1 and CDR3 of a light chain variable region are respectively shown as SEQ ID NO: 4 and SEQ ID NO: 5, and an amino acid sequence of a complementary determining region CDR2 is GAT. The monoclonal antibody can specifically bind to RTN4RL2 and has high affinity to RTN4RL2, in addition, T cell proliferation experiments show that the monoclonal antibody has a remarkable blocking effect on the T cell inhibition effect mediated by RTN4RL2, therefore, the monoclonal antibody can activate anti-tumor immune response by blocking the T cell inhibition effect of RTN4RL2, and a wide anti-tumor application prospect is shown.

This invention provides a CD147-targeting nano-ultrasound contrast agent, its preparation method, and its application. The contrast agent comprises: microbial-derived gas vesicles and CD147 nanoantibodies linked to the surface of the gas vesicles via a coupling agent. The hollow nanostructure of the gas vesicles in this invention endows the contrast agent with highly efficient acoustic reflection capabilities, significantly improving the ultrasound signal intensity. The CD147 nanoantibodies possess high affinity and high specificity, enabling precise recognition of the CD147 antigen on the surface of tumor cells. This invention uses biosynthesized gas vesicles instead of traditional chemically synthesized gas microbubbles, combined with a simple and efficient coupling process, significantly reducing preparation difficulty and equipment dependence. The contrast agent of this invention overcomes the shortcomings of existing technologies in imaging performance, targeting, preparation process, safety, and multifunctional diagnostic and therapeutic capabilities, providing a novel technical pathway for precision diagnosis and treatment of tumors.

This application provides a monoclonal antibody combination against NFL protein and its uses. The monoclonal antibody combination includes a first antibody and a second antibody. The first antibody includes a first heavy chain variable region and a first light chain variable region, and the second antibody includes a second heavy chain variable region and a second light chain variable region. The first heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:3-5, the first light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:6-8, the second heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:11-13, and the second light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:14-16. The monoclonal antibody combination provided in this embodiment has excellent specificity and high affinity, and can be used for in vitro quantitative detection of serum NFL concentration, providing technical support for the auxiliary diagnosis of neurological diseases.

The invention relates to the technical field of immunodetection, in particular to an anti-TPO antibody or an antigen binding fragment thereof. The anti-TPO antibody provided by the invention has the characteristics of high affinity and good stability, and provides a raw material source with excellent performance for the preparation of a calibration product / a positive control product / a quality control product of a TPO antibody detection kit.

This invention discloses an APLN monoclonal antibody, its preparation method, and its applications. The APLN monoclonal antibody includes a light chain variable region and a heavy chain variable region. The amino acid sequence of the light chain variable region is shown in SEQ ID No:1, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No:2. The APLN monoclonal antibody is obtained by immunizing mice with APLN protein, followed by single-cell B-cell sorting and single-cell PCR. Utilizing advanced single-cell B-cell cloning technology combined with single-cell PCR, a novel APLN monoclonal antibody has been developed. The obtained antibody sequence is the result of natural affinity maturation screening by the in vivo immune system, requiring no additional humanization or in vitro affinity maturation steps. It retains the natural high affinity and specificity, and can directly obtain all-natural antibodies with high affinity and high specificity.

This invention belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer-specific nucleic acid aptamer, nucleic acid aptamer derivatives, and their applications. The nucleotide sequences of the nucleic acid aptamer are shown in SEQ ID NO: 1, 2, and 3. This invention screened three monoclonal nucleic acid aptamer DNA chains from bladder cancer tissue samples using the exponential enrichment systematic evolution (SELEX) technique and identified two target proteins that bind to these three nucleic acid aptamers. The nucleic acid aptamers specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells. The nucleic acid aptamers obtained by this invention have advantages such as high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, and ease of storage and labeling, providing a new molecular tool for the early diagnosis and targeted therapy of bladder cancer.

This invention discloses a method for the specific detection of human S100ββ homodimer using a single monoclonal antibody. This monoclonal antibody exhibits high specificity and high affinity for recognizing the human S100β subunit, and its heavy and light chain variable region amino acid sequences are shown in SEQ ID NO.1 and SEQ ID NO.5. A specific S100ββ homodimer double-antibody sandwich detection method is established by simultaneously using this monoclonal antibody or its antigen-binding fragment as both the capture antibody and the detection antibody, binding to the same epitope sites on both subunits of the S100ββ homodimer. This method achieves a limit of detection of 0.005 ng / mL for S100ββ homodimer, with a detection linear range of 0.005–10 ng / mL. This method is suitable for the specific detection of S100ββ homodimer.

The present invention relates to: humanized antibodies capable of specifically binding to TransMembrane 4 Superfamily Member 4 (TM4SF4) with high affinity and showing low immunogenicity in humans; and a composition for preventing and treating cancer or assisting in immune anticancer therapy, the composition comprising the humanized antibodies.

A method is derived for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.

Provided is a method for constructing a nanobody-encoding DNA library. The method comprises: using an immunogen to screen peripheral blood mononuclear cells (PBMCs) of an animal to obtain positive cells specifically binding to the immunogen; and amplifying nucleic acid samples derived from the positive cells to obtain a nanobody-encoding DNA library, wherein the nanobody is a nanobody specifically binding to the immunogen, and wherein the amplifying comprises using one or more groups of primer pairs, and each group of primer pairs among the one or more groups of primer pairs comprises one or more forward primers and one or more reverse primers. In the present invention, a large number of diverse DNA sequences containing a large number of low-abundance sequences are obtained. A high-throughput sequencing-based technical route for rapid preparation of a VHH antibody allows for efficient and rapid acquisition of the VHH antibody having high affinity and high specificity, thereby satisfying a raw material requirement of a high-quality diagnostic agent.

This invention discloses a method for preparing a secondary antibody and its application, belonging to the fields of biomedicine and bioengineering technology. The invention specifically designs an efficient multidimensional chromatographic purification strategy, sequentially passing the serum to be purified through four chromatographic columns: affinity capture (recovering IgG target molecules and removing most plasma protein impurities); antigen affinity enrichment (further enriching antibody subpopulations with high affinity and specificity to the target antigen, reducing the coexistence of non-specific subpopulations); tandem cross-adsorption (removing antibody subpopulations that cross-react to non-target species and reducing potential non-specific binding); and size exclusion / gel filtration (removing high molecular weight aggregates and low molecular weight residues, and achieving final buffer replacement and sample homogenization). The secondary antibody prepared by this invention exhibits significantly better sensitivity, specificity, and batch-to-batch consistency than existing technologies, with sensitivity improved by approximately 57% and specificity greatly enhanced compared to conventional techniques.

In the present invention, cyclic dinucleotides or their compositions are used as biological response modifiers to enhance the immune response of subjects with deficient immune systems, with a low or absent response to vaccine antigens, or with a deficient immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in such a way as to eliminate the lack of response, resulting in the development of a high-avid immune response that prevents disease caused by infectious agents, particularly viruses with the ability to evade immune surveillance mechanisms and, consequently, suppress the induction of an effective, high-avid adaptive response.The present invention also comprises cyclic dinucleotide formulations, which can be administered alone, in combination with other biological response modifiers, or in vaccine formulations with antigens. The proposed invention further includes a method for preventing or treating acute respiratory infections, preventing disease severity, and blocking transmission by inducing an immune response at the point of entry (nasopharyngeal mucosa), preventing or reducing person-to-person transmission of pathogens / viruses in preventive vaccine formulations, as well as in formulations used for prophylaxis before and after exposure to acute respiratory infections.

The humanized monoclonal antibodies and the antibody drug conjugates targeting CD276 (B7-H3), derived from the murine monoclonal antibody clone 8H9. These antibodies and the antibody drug conjugates exhibit high affinity and specificity for human CD276, a member of the B7 family of immune regulatory proteins, which is overexpressed in various tumors and involved in immune checkpoint modulation. The humanized antibodies and the antibody drug conjugates are applied for targeted treatment of cancers and refractory diseases.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The present application relates to a kind of anti-procambarus clarkii white spot syndrome virus monoclonal antibody and its application, the complementary determining region CDR1-3 sequence of the heavy chain variable region of the anti-procambarus clarkii white spot syndrome virus monoclonal antibody is sequentially shown as SEQ ID NO:3-5, the complementary determining region CDR1-3 sequence of the light chain variable region is sequentially shown as SEQ ID NO:6-8.The present application successfully obtains the high affinity of anti-VP28 monoclonal antibody, and it has excellent affinity to procambarus clarkii white spot syndrome virus.The monoclonal antibody can be used for specific detection to procambarus clarkii white spot syndrome virus, and has good virus neutralization activity.By adding the monoclonal antibody in water body, the resistance of procambarus clarkii to white spot syndrome virus can be greatly improved, easy to operate, without injection, suitable for large-scale breeding scene, provide a new technical means for the prevention and control of white spot syndrome virus disease in aquaculture.

The application provides a Mycobacterium tuberculosis EspB monoclonal antibody, a preparation method and application thereof, and relates to the technical field of antibodies. The Mycobacterium tuberculosis EspB monoclonal antibody is obtained by immunizing animals with Mycobacterium tuberculosis cell walls and screening the monoclonal antibody through a phage antibody library technology. The application discloses the Mycobacterium tuberculosis EspB monoclonal antibody or a functional fragment thereof, and application thereof as an antibody conjugate and a composition. The monoclonal antibody has a specific nucleic acid sequence, and codes the specific EspB monoclonal antibody or the functional fragment thereof. The EspB monoclonal antibody obtained by the application has the characteristics of high sensitivity, high specificity and high affinity.

The application belongs to the technical field of biotechnology, and particularly relates to an anti-TL1A nanobody and application thereof. The amino acid sequences of the complementarity determining regions CDR1, CDR2 and CDR3 of the nanobody are respectively shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:1. The application uses a llama natural nanobody library and combines phage display technology to successfully screen a high-affinity nanobody targeting TL1A. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physicochemical stability. Based on the characteristic of targeting TL1A, the nanobody has important application value in the precise diagnosis and targeted treatment of TL1A high-expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is particularly suitable for developing a high-sensitivity in-vitro diagnostic kit and a novel biological therapeutic drug.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-CD22 nanobody and a preparation method and application thereof. The anti-CD22 nanobody comprises a framework region and a complementarity determining region, wherein the complementarity determining region comprises CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2) and CDR3 (SEQ ID NO: 3). The preparation method comprises the following steps: immunizing a llama with a Human CD22 / His protein, extracting RNA from PBMC cells and reverse transcribing the RNA into cDNA, constructing a phage display library, obtaining a positive clone through CD22 antigen protein panning after sequencing analysis, and expressing the antibody through a mammalian cell expression system. The application adopts an optimized phage display technology, has a short screening cycle, and the obtained nanobody has a small molecular weight, a stable structure and high affinity to CD22. The antibody can be efficiently expressed through a mammalian cell, and retains natural modification activity.

The present disclosure provides anti-5T4 antibodies, variants and humanized forms thereof. The newly disclosed antibodies exhibit high affinity for 5T4 protein and are useful for treating cancer.

Provided are an anti-canine PD-1 antibody and the use thereof in the prevention and treatment of tumors in mammals, especially the use in the prevention and treatment of canine tumors. The canine PD-1 antibody having high affinity and high activity can block the binding of canine PD-1 and a ligand thereof, thus achieving the purpose of treating canine tumor diseases.

This invention discloses a monoclonal antibody against Oit3 protein in mouse hepatic sinusoidal endothelial cells or its antigen-binding fragment and its applications, belonging to the fields of biotechnology and medical immunology. The monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region contains HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NO. 3~SEQ ID NO. 5; the light chain variable region contains LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NO. 8~SEQ ID NO. 10. This monoclonal antibody and the recombinant fluorescent antibody exhibit high affinity and high specificity, and can be effectively applied to enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunofluorescence detection. They can serve as important antibody tools for basic research on mouse hepatic sinusoidal endothelial cells and for exploring the mechanisms of liver diseases. Based on its variable region sequence, a recombinant fluorescent antibody, Oit3-scFv-GFP, was also constructed. This recombinant fluorescent antibody enables one-step direct immunofluorescence staining, providing a convenient tool for in situ visualization of mouse hepatic sinusoidal endothelial cells.

This invention belongs to the field of biotechnology and provides an anti-LY6G6D antibody or its antigen-binding fragment and its uses. The antibody or its antigen-binding fragment provided by this invention has a high affinity for human LY6G6D and has excellent prospects for drug development.